Methodological Approaches to Ketogenic Dietary Treatments in Glioma Patients from a Nutritional Point of View

Abstract

Ketogenic diets (KD) have received increasing interest in neuro-oncology based on their ability to inhibit glioma growth in vitro and their established role in medically refractory seizures. This review analyses the methodological aspects of KD treatment alongside standard care for patients with gliomas from a nutritional point of view. A literature search was performed in March 2022 searching PubMed and Scopus. we identified 13 articles including 187 patients with a histological-new or recurrent-diagnosis of glioma and treated by KD during the course of the disease. Dietary treatments were categorized as the classical ketogenic diet (CKD), the Modified Atkins diet (MAD), and the medium-chain triglyceride (MCT) diet. we identified a large variation in dietary characteristics regarding restriction of carbohydrates, ketogenic ratio, and additional dietary support. This striking heterogenicity in the methodological approaches of KD treatments made it problematic to compare effects between the included studies. Therefore, a standardized definition of KD for patients with glioma and a consensus on methodological implementation is needed. it would also be desirable to further investigate to what extent KD treatment can be optimized to secure optimal nutrient status and patient satisfaction.

Dietary carbohydrates in the management of epilepsy

“…Gastrointestinal disturbances are the most common side effects on dietary therapy. This is more commonly seen in the CKD than the MAD group [27].…”